Google_______________

Central Fat Deposition / Fat Accumulation (Lipohypertrophy)


Theratechnologies Announces Promising 52-week Study Data on Tesamorelin (TH9507) for Treatment of Lipodystrophy in HIV Patients - 10/05/07

Switching to Lopinavir/Ritonavir (Kaletra) plus Efavirenz (Sustiva) Increases Limb Fat, but also Raises Blood Lipid Levels    - 7/03/07

No Significant Body Composition Differences between Patients Treated with Atazanavir vs Atazanavir/ritonavir  - 3/20/07

TH9507 Growth Hormone-releasing Factor Decreases Visceral Abdominal Fat and Improves Lipid Profiles  - 3/09/07

"Buffalo Hump" Linked to Use of d4T 2/16/07

Body Shape Changes in Women who Discontinue d4T  1/16/07

Rosiglitazone and Metformin Improve Insulin Sensitivity, but Minimal Effect on Body Fat  12/12/06

Does Discontinuation of Stavudine or Protease Inhibitor Therapy Improve HIV-related fat Redistribution in Men? - 5/05/06

Outcomes from Discontinuing Stavudine or Protease Inhibitor Therapy for HIV Fat Redistribution- 2/24/06

Metabolic and Adverse Events Report from the 13th CROI - 2/21/06

Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Treatment-naive HIV Patients - 1/17//06

Lipid Changes in a Randomised, 48-week, Open Label Comparative Study of Tenofovir DF vs. Abacavir as Substitutes for a Thymidine Analog in Persons with Lipoatrophy: The RAVE Study. G Moyle and others. - 12/18/05

Increase in Limb Fat after Stopping Nucleoside Analogue Therapy Is Not Associated with Decreased Visceral Fat and Has Different Risk Factors - 12/09/05

Risk Factors for Lipoatrophy - 12/09/05

Supplementation with Creatine Does Not Improve the Benefits from Resistance Exercise Training in HIV Patients - 12/09/05

Single Dose of Amprenavir Does Not Induce Insulin Resistance - 12/09/05

Body Fat Changes in Children with HIV Infection - 12/09/05

Visceral Fat Mass and the Risk of Insulin Resistance and Cardiovascular Disease - 12/09/05

HIV Patients with Lipoatrophy Have High Levels of Anxiety and Depression and Low Self Esteem with Poorer Quality of Life - 12/09/05

Anthropometry and Bioimpedance Are Inexpensive Office-based Assessments of Body Shape Changes in Patients on HAART - 12/09/05

Is Fat Mass Ratio an Objective Tool for Diagnosis of HIV Lipodystrophy Syndrome Diagnosis? - 12/09/05

Patient Perspective Is Essential in Medical Decision-making about Lipodystrophy - 12/09/05

Body Shape Changes 1 and 2 Years after Switch to Tenofovir from Stavudine - 12/09/05

CD4+ Cell Count, Viral Load and HAART Independently Predict Body Composition Changes in HIV Positive Adults - 11/30/05

FRAM Study Finds No Association between Fat Loss and Fat Accumulation in Men with HIV on Antiretroviral Therapy - 10/03/05

Comparison of Rosiglitazone and Metformin for Treatment of HIV-related Lipodystrophy - 9/19/05

Impact of Rosiglitazone Treatment on the Bioavailability of Antiretroviral Drugs in HIV Patients - 9/19/05

Fat Loss and Fat Accumulation in HIV Patients Are Distinct Syndromes with No Common Factor Underlying Their Prevalence - 6/24/05

Therapeutic Approaches to Combating Lipoatrophy: Do They Work? - 6/17/05

Serono Completes Clinical Milestone in Phase III Trial of Human Growth Hormone (Serostim) for HIV-associated Adipose Redistribution Syndrome (HARS) - 6/17/05

Metabolic Benefits But No Morphological Improvements 24 Months after Replacing a Protease Inhibitor with Abacavir, Efavirenz or Nevirapine - 6/01/05

Fat Redistribution Predicts Cardiac Risk in Women with HIV - 5/27/05

Body Image in Patients with HIV: Assessment of a New Psychometric Measure - 4/06/05

Data at 12th CROI Builds Optimism on Metabolic and Morphologic Management - 3/11/05

Antiretroviral Therapy-related Adverse Events Data Presented at the 12th CROI - 3/11/05

Body Shape Changes in a Cohort of HIV Positive and HIV Negative Injection Drug Users - 2/02/05

Serono Completes Enrollment for Phase III Trial of Serostim for HIV-associated Fat Redistribution - 1/26/05

Buffalo Hump

"Buffalo Hump" Linked to Use of d4T 2/16/07

Body Image in Patients with HIV: Assessment of a New Psychometric Measure - 4/06/05

Buffalo Hump Seen in HIV-Associated Lipodystrophy Is Associated with Hyperinsulinemia But Not Dyslipidemia - 1/28/05





 

 

 

 

 

 

 

 

 

 

 

 

 










HIV and AIDS Treatments
FDA-Approved

Protease Inhibitors

Agenerase (amprenavir)
Aptivus (Tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva (Fosamprenavir)
Norvir (ritonavir)
Reyataz (atazanavir)
Viracept (nelfinavir)


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir (AZT plus 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir
- (abacavir/zidovudine/lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors

Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors

 Fuzeon (enfuvirtide; T-20)